Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience

Major advances in sequencing technologies and targeted therapies have accelerated the incorporation of oncology into the era of precision medicine and “biomarker-driven” treatments. However, the impact of this approach on the everyday clinic has yet to be determined. Most precision oncology reports...

Descripción completa

Detalles Bibliográficos
Autores principales: Cordova-Delgado, Miguel, Pinto, Mauricio P., Regonesi, Carlos, Cereceda, Luis, Reyes, José Miguel, Itriago, Laura, Majlis, Alejandro, Rodríguez, Pablo, Fassler, André, Mahave, Mauricio, León, María Elisa, Gallardo, Jorge, Rodríguez Z., María Paz, Berkovits, Alejandro, Manque, Patricio, Ríos, Juvenal A., Garcia-Bloj, Benjamín, Garrido, Marcelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879850/
https://www.ncbi.nlm.nih.gov/pubmed/35207683
http://dx.doi.org/10.3390/jpm12020195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879850/
https://www.ncbi.nlm.nih.gov/pubmed/35207683
http://dx.doi.org/10.3390/jpm12020195

Ejemplares similares